State Street’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

State Street’s Portfolio ANTH Stock Details ANTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-84,811	Closed	-$287K	–	3767
2017 Q1	$287K	Sell	84,811 -425	-0.5%	-$2.01K	﹤0.01%	3467
2016 Q4	$445K	Sell	85,236 -2,866	-3%	-$49.6K	﹤0.01%	3407
2016 Q3	$2.22M	Sell	88,102 -11,005	-11%	-$278K	﹤0.01%	2930
2016 Q2	$2.45M	Buy	99,107 +29,569	+43%	+$835K	﹤0.01%	2946
2016 Q1	$2.01M	Buy	69,538 +4,278	+7%	+$116K	﹤0.01%	3002
2015 Q4	$2.42M	Buy	65,260 +743	+1%	+$32.8K	﹤0.01%	2918
2015 Q3	$3.14M	Buy	64,517 +22,458	+53%	+$1.57M	﹤0.01%	2774
2015 Q2	$2.9M	Buy	+42,059	New	+$1.95M	﹤0.01%	2911
2013 Q3	–	Sell	-595	Closed	-$17K	–	3645
2013 Q2	$17K	Buy	+595	New	+$22.2K	﹤0.01%	3530

Other funds holding ANTH

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

ECM

Element Capital Management New York $3.2B AUM 29.54% 1-Year Est. Return

State Street's ANTH Position: Q2 2017 in Review

State Street sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q2 2017, closing a stake of 84,811 shares — an estimated $287K sold.

State Street first reported a position in ANTH in Q2 2013 and held it in 9 quarters. The position peaked at $3.14M in Q3 2015. 40 funds tracked by Wall St. Rank hold ANTH as of Q2 2017.

State Street reported no remaining Anthera Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
State Street sold 84,811 Anthera Pharmaceuticals, Inc. shares in Q2 2017, an estimated $287K.
State Street first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2013 and held it in 9 quarters.
State Street's Anthera Pharmaceuticals, Inc. position peaked at $3.14M in Q3 2015.
40 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q2 2017.

Based on State Street's 13F filing for Q2 2017, filed 14 Aug 2017.